A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
Phase of Trial: Phase IV
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Exenatide; Insulin detemir
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 26 Apr 2012 Actual end date (1 Feb 2010) added as reported by ClinicalTrials.gov.
- 26 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.